Michael E Luggen , MD

Bachelor's Degree: Harvard College 1970

Bachelor's Degree: Dartmouth Medical School 1972 (Biomedical Science )

Medical Degree: Columbia University 1974

Residency : University of Cincinnati 1977 (Internal Medicine)

Fellowship: University of Cincinnati 1982 (Division of Immunology )

American Board of Internal Medicine (Certification Date: 09-13-1978 )

American Board of Internal Medicine (Rheumatology) (Certification Date: 11-09-1982 )

Rheumatology

Ankylosing Spondylitis

Autoimmune Vasculitis

Behcet Syndrome (Neuro-Bechet)

Central Nervous System Lupus Vasculitis

Collagen Disease

CREST Syndrome

Cryoglobulinemia

Cutaneous, Leukocytoclastic, Vasculitis

Gout

Hip Rheumatoid Arthritis

Lupus (Systemic lupus erythematosus)

Lupus Erythematosus Panniculitis

Lupus Nephritis

Microscopic Polyangiitis

Mixed Connective Tissue Disease (MCTD)

Osteochondritis Dissecans

Overlap Connective Tissue Disease

Paget Disease

Polymyalgia Rheumatica

Polymyositis

Polymyositis/Dermatomyositis

Pseudogout

Psoriatic Arthritis

Raynaud Phenomenon in Scleroderma

Raynaud's Disease

Reactive Arthritis (Reiter's Syndrome)

Rheumatoid Arthritis

Rheumatoid Vasculitis

Still's Disease

Systemic Lupus Erythematosus (SLE)

Systemic Vasculitis

Takayasu Arteritis

Temporal Arteritis (Giant cell arteritis)

Vasculitis (Angiitis)

Weill-Marchesani Syndrome

Internal Medicine

Rheumatology

Evaluation of New Therapies for RA and Epidemiologic Studies on the Influence of Race on Outcome of RA.

2004 -To Present Professor of Clinical Medicine, University of Cincinnati, Cincinnati, OH

1989 -2004 Associate Professor of Clinical Medicine, University of Cincinnati College of Medicine, Cincinnati, OH

1982 -1989 Assistant Professor of Clinical Medicine, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH

1985 -1988 Assistant Professor of Clinical Pathology, Department of Pathology, University of Cincinnati College of Medicine, Cincinnati, OH

10-01-2008 -09-30-2009 Lupus Foundation of America Cognitive dysfunction in systemic lupus erythematosis: its diagnosis, prognosis, and clinical significance Role:PI $75,000

Investigators:JF Fries, ME Luggen 04-01-2002 -03-31-2006 National Instititues of Health ARAMIS 2006 Project 2: "The Influence of Race on Outcome in Rheumatoid Arthritis" Project 3: "Long-term Complications of Rheumatoid Arthritis and its Treatment" Role:Co-I $89,000

Investigators:JF Fries, ME Luggen 04-01-1996 -03-31-2001 National Institutes of Health "Improving Long-term Outcomes in Arthritis: ARAMIS 2000" Project 4: "Toward Better Oucomes in Osteoarthritis: Finding an Appropriate Role for Non-steroidal Anti-inflammatory Drugs" Role:Co-I $171,700

12-01-1994 -11-30-1997 Arthritis Foundation, Southwestern Ohio Chapter Hematologic Toxicity of Methotrexate in Rheumatology Practice Role:PI

07-01-1992 -06-30-1994 Upjohn Company The Effects of Flurbiprofen on the in vivo Biomechanical Properties of Bone in Rheumatoid and Osteoarthritis Role:PI $20,000

Grant: #PY-1970-14793-C / P01-AR-43584 Investigators:Luggen, Michael 04-08-2002 -12-31-2006 National Institute of Arthritis, Musculoskeletal and Skin Disease Aramis 2006: Toward Patient Outcomes in Arthritis Role:PI $77,646.00 Closed Level:Federal

Grant: #5-R18-AR-21393-25-A0-S0-E0 Investigators:Luggen, Michael 07-01-1996 -12-31-2002 National Institute of Arthritis, Musculoskeletal and Skin Disease Improving Long Term Outcomes in Arthritis: ARAMIS 2000 Role:PI $156,384.00 Closed Level:Federal

Grant: #SRS 005966 Investigators:Luggen, Michael; Shukla, Rakesh 10-01-2008 -12-31-2010 Lupus Foundation of America Cognitive dysfunction in SLE: Diagnosis, Prognosis, and Significance Role:PI $75,000.00 Closed Level:Private Non-Profit

Grant: #PVT-2201-301 Investigators:Luggen, Michael 02-27-2023 -02-26-2026 Premier Research International LLC "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis" Role:PI 0.00 Hold Level:Industry

Grant: #C07-03-02 Investigators:Luggen, Michael 09-15-2023 -09-15-2026 Biogen Idec Inc. A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 in Adult Participants with Active Systemic Lupus Erythematosus Role:PI 357139.02 Hold Level:Industry

Grant: #C07-03-02 Investigators:Luggen, Michael 09-15-2023 -09-15-2026 IQVIA Clinical Trial Payments A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 in Adult Participants with Active Systemic Lupus Erythematosus Role:PI 0.00 Hold Level:Industry

Grant: #C07-03-02 Investigators:Luggen, Michael 09-15-2023 -09-15-2026 IQVIA Clinical Trial Payments A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 in Adult Participants with Active Systemic Lupus Erythematosus Role:PI 0.00 Hold Level:Industry

Grant: #M23-699 Investigators:Luggen, Michael 12-07-2023 -12-07-2023 AbbVie, Inc. SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib inSubjects with Moderately to Severely Active SLE Role:PI 597257.75 Hold Level:Industry

Peer Reviewed Publications

Chalhoub, N E; Luggen, M E (2019. ) Screening for cognitive dysfunction in systemic lupus erythematosus: the Montreal Cognitive Assessment Questionnaire and the Informant Questionnaire on Cognitive Decline in the Elderly.Lupus, , 28 (1 ) ,51-58 More Information

Gulati, Gaurav; Iffland, Philip H; Janigro, Damir; Zhang, Bin; Luggen, Michael E (2016. ) Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction.Clinical rheumatology, , 35 (12 ) ,2989-2997 More Information

Luggen, Michael E; Gulati, Gaurav; Zhang, Bin; Willis, Rohan A; Gonzalez, Emilio B (2016. ) Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE.Clinical rheumatology, , 35 (1 ) ,93-9 More Information

Antonchak, Marc A; Saoudian, Mahnaz; Khan, Amber R; Brunner, Hermine I; Luggen, Michael E (2011. ) Cognitive dysfunction in patients with systemic lupus erythematosus: a controlled study.The Journal of rheumatology, , 38 (6 ) ,1020-5 More Information

Wasko, Mary Chester M; Hubert, Helen B; Lingala, Vijaya Bharathi; Elliott, Jennifer R; Luggen, Michael E; Fries, James F; Ward, Michael M (2007. ) Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.JAMA, , 298 (2 ) ,187-93 More Information

Kremer, Joel M; Genovese, Mark C; Cannon, Grant W; Caldwell, Jacques R; Cush, John J; Furst, Daniel E; Luggen, Michael E; Keystone, Ed; Weisman, Michael H; Bensen, William M; Kaine, Jeffrey L; Ruderman, Eric M; Coleman, Patricia; Curtis, David L; Kopp, Elliot J; Kantor, Seth M; Waltuck, Jonathan; Lindsley, Herbert B; Markenson, Joseph A; Strand, Vibeke; Crawford, Bruce; Fernando, Indra; Simpson, Karen; Bathon, Joan M (2002. ) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.Annals of internal medicine, , 137 (9 ) ,726-33 More Information

Mould, D R; Davis, C B; Minthorn, E A; Kwok, D C; Elliott, M J; Luggen, M E; Totoritis, M C (1999. ) A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.Clinical pharmacology and therapeutics, , 66 (3 ) ,246-57 More Information

Williams, H J; Alarcon, G S; Joks, R; Steen, V D; Bulpitt, K; Clegg, D O; Ziminski, C M; Luggen, M E; St Clair, E W; Willkens, R F; Yarboro, C; Morgan, J G; Egger, M J; Ward, J R (1999. ) Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. The Journal of rheumatology, , 26 (4 ) ,816-25

Williams, H J; Alarcón, G S; Neuner, R; Steen, V D; Bulpitt, K; Clegg, D O; Ziminski, C M; Luggen, M E; Polisson, R P; Willkens, R F; Yarboro, C; Morgan, J; Egger, M J; Ward, J R (1998. ) Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases. The Journal of rheumatology, , 25 (2 ) ,261-8

Clegg, D O; Reda, D J; Mejias, E; Cannon, G W; Weisman, M H; Taylor, T; Budiman-Mak, E; Blackburn, W D; Vasey, F B; Mahowald, M L; Cush, J J; Schumacher, H R; Silverman, S L; Alepa, F P; Luggen, M E; Cohen, M R; Makkena, R; Haakenson, C M; Ward, R H; Manaster, B J; Anderson, R J; Ward, J R; Henderson, W G (1996. ) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study.Arthritis and rheumatism, , 39 (12 ) ,2013-20 More Information

Clegg, D O; Reda, D J; Weisman, M H; Blackburn, W D; Cush, J J; Cannon, G W; Mahowald, M L; Schumacher, H R; Taylor, T; Budiman-Mak, E; Cohen, M R; Vasey, F B; Luggen, M E; Mejias, E; Silverman, S L; Makkena, R; Alepa, F P; Buxbaum, J; Haakenson, C M; Ward, R H; Manaster, B J; Anderson, R J; Ward, J R; Henderson, W G (1996. ) Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study.Arthritis and rheumatism, , 39 (12 ) ,2004-12 More Information

Alarcón, G S; Willkens, R F; Ward, J R; Clegg, D O; Morgan, J G; Ma, K N; Singer, J Z; Steen, V D; Paulus, H E; Luggen, M E; Polisson, R P; Ziminski, C M; Yarboro, C; Williams, H J (1996. ) Early undifferentiated connective tissue disease. IV.Musculoskeletal manifestations in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of patients with well-established connective tissue diseases: followup analyses in patients with unexplained polyarthritis and patients with rheumatoid arthritis at baseline.Arthritis and rheumatism, , 39 (3 ) ,403-14 More Information

Luggen, M E (1994. ) [Duration of use of non-steroidal anti-inflammatory agents in patients with rheumatoid arthritis]. Revue du rhumatisme (Ed. francaise : 1993), , 61 (10 Pt 2 ) ,165S-172S

Bulpitt, K J; Clements, P J; Lachenbruch, P A; Paulus, H E; Peter, J B; Agopian, M S; Singer, J Z; Steen, V D; Clegg, D O; Ziminski, C M; Alarcon, G S; Luggen, M E; Polisson, R P; Willkens, R F; Reading, J C; Williams, H J; Ward, J R (1993. ) Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis).Annals of internal medicine, , 118 (8 ) ,602-9 More Information

Clegg, D O; Williams, H J; Singer, J Z; Steen, V D; Schlegel, S; Ziminski, C; Alarcón, G S; Luggen, M E; Polisson, R P; Willkens, R F (1991. ) Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. The Journal of rheumatology, , 18 (9 ) ,1340-3

Alarcón, G S; Williams, G V; Singer, J Z; Steen, V D; Clegg, D O; Paulus, H E; Billingsley, L M; Luggen, M E; Polisson, R P; Willkens, R F (1991. ) Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. The Journal of rheumatology, , 18 (9 ) ,1332-9

Bendon, R W; Hayden, L E; Hurtubise, P E; Getahun, B; Siddiqi, T A; Glueck, H I; Luggen, M E; Gartside, P S (1990. ) Prenatal screening for anticardiolipin antibody.American journal of perinatology, , 7 (3 ) ,245-50 More Information

Luggen, M E; Gartside, P S; Hess, E V (1989. ) Nonsteroidal antiinflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value. The Journal of rheumatology, , 16 (12 ) ,1565-9

Hess, E V; Luggen, M E (1989. ) Remodeling the pyramid--a concept whose time has not yet come. The Journal of rheumatology, , 16 (9 ) ,1175-6

Fritz, D A; Luggen, M E; Hess, E V (1989. ) Unusual longevity in primary systemic amyloidosis: a 19-year survivor.The American journal of medicine, , 86 (2 ) ,245-8 More Information

Williams, H J; Ward, J R; Dahl, S L; Clegg, D O; Willkens, R F; Oglesby, T; Weisman, M H; Schlegel, S; Michaels, R M; Luggen, M E (1988. ) A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis.Arthritis and rheumatism, , 31 (6 ) ,702-13 More Information

Thun, M; Tanaka, S; Smith, A B; Halperin, W E; Lee, S T; Luggen, M E; Hess, E V (1987. ) Morbidity from repetitive knee trauma in carpet and floor layers.British journal of industrial medicine, , 44 (9 ) ,611-20 More Information

Alarcón, G S; Billingsley, L M; Clegg, D O; Hardin, J G; Klippel, J; Luggen, M E; Polisson, R P; Singer, J Z; Szydlo, L; Willkens, R F (1987. ) Lack of association between HLA-DR2 and clinical response to methotrexate in patients with rheumatoid arthritis.Arthritis and rheumatism, , 30 (2 ) ,218-20 More Information

Williams, H J; Willkens, R F; Samuelson, C O; Alarcón, G S; Guttadauria, M; Yarboro, C; Polisson, R P; Weiner, S R; Luggen, M E; Billingsley, L M (1985. ) Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.Arthritis and rheumatism, , 28 (7 ) ,721-30 More Information

Tanaka, S; Halperin, W E; Smith, A B; Lee, S T; Luggen, M E; Hess, E V (1985. ) Skin effects of occupational kneeling.American journal of industrial medicine, , 8 (4-5 ) ,341-9 More Information

Stewart, J; Luggen, M E; Valtin, H (1972. ) A computer model of the renal countercurrent system.Kidney international, , 2 (5 ) ,253-63 More Information

Genovese M.C.;Schiff M.;Luggen M.;Le Bars M.;Aranda R.;Elegbe A.;Dougados M. (08-01-2012. ) Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid a.Journal of Rheumatology, , 39 (8 ) ,1546-1554 More Information

Keystone E.;Kremer J.;Russell A.;Box J.;Abud-Mendoza C.;Elizondo M.;Luo A.;Aranda R.;Delaet I.;Swanink R.;Gujrathi S.;Luggen M. (06-01-2012. ) Abatacept in subjects who switch from intravenous to subcutaneous therapy: Results from the phase II.Annals of the Rheumatic Diseases, , 71 (6 ) ,857-861 More Information

Adhikari T.;Piatti A.;Luggen M. (10-01-2011. ) Cognitive dysfunction in SLE: Development of a screening tool.Lupus, , 20 (11 ) ,1142-1146 More Information

Kocharla L.;Taylor J.;Weiler T.;Ting T.;Luggen M.;Brunner H. (12-01-2009. ) Monitoring methotrexate toxicity in juvenile idiopathic arthritis.Journal of Rheumatology, , 36 (12 ) ,2813-2818 More Information

Genovese M.C.;Schiff M.;Luggen M.;Becker J.C.;Aranda R.;Teng J.;Li T.;Schmidely N.;Le Bars M.;Dougados M. (04-01-2008. ) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatme.Annals of the Rheumatic Diseases, , 67 (4 ) ,547-554 More Information

Wasko M.;Hubert H.;Lingala V.;Elliott J.;Luggen M.;Fries J.;Ward M. (11-28-2007. ) Risk of diabetes in patients with rheumatoid arthritis taking hydroxychloroquine: Reply [5].Journal of the American Medical Association, , 298 (20 ) ,2369-2370 More Information

Vincenti F.;Luggen M. (05-11-2007. ) T cell costimulation: A rational target in the therapeutic armamentarium for autoimmune diseases and.Annual Review of Medicine, , 58 ,347-358 More Information

Weinblatt M.;Schiff M.;Goldman A.;Kremer J.;Luggen M.;Li T.;Chen D.;Becker J. (02-01-2007. ) Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis whil.Annals of the Rheumatic Diseases, , 66 (2 ) ,228-234 More Information

Ahmed M.;Luggen M.;Herman J.;Weiss K.;Decourten-Myers G.;Quinlan J.;Khanna D. (11-01-2006. ) Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration .Journal of Rheumatology, , 33 (11 ) ,2344-2346

Genovese M.C.;Becker J.C.;Schiff M.;Luggen M.;Sherrer Y.;Kremer J.;Birbara C.;Box J.;Natarajan K.;Nuamah I.;Li T.;Aranda R.;Hagerty D.T.;Dougados M. (09-15-2005. ) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor ? inhibition.New England Journal of Medicine, , 353 (11 ) ,1114-1123 More Information

Kremer J.;Genovese M.;Cannon G.W.;Caldwell J.;Cush J.;Furst D.E.;Luggen M.;Keystone E.;Bathon J.;Kavanaugh A.;Ruderman E.;Coleman P.;Curtis D.;Kopp E.;Kantor S.;Weisman M.;Waltuck J.;Lindsley H.B.;Markenson J.;Crawford B.;Fernando I.;Simpson K.;Strand V. (08-01-2004. ) Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis .Journal of Rheumatology, , 31 (8 ) ,1521-1531

Luggen M. (02-01-2004. ) Trials Are Short, Disease Long: Measuring Drug Utility Beyond Clinical Trials .Journal of Rheumatology, , 31 (2 ) ,205-206

Moreland L.W.;Alten R.;Van Den Bosch F.;Appelboom T.;Leon M.;Emery P.;Cohen S.;Luggen M.;Shergy W.;Nuamah I.;Becker J.C. (06-22-2002. ) Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, p.Arthritis and Rheumatism, , 46 (6 ) ,1470-1479 More Information

Farhey Y.;Luggen M. (01-01-1998. ) Seropositive, symmetric polyarthritis in a patient with poorly differentiated lung carcinoma: Carcin.Arthritis and Rheumatism, , 11 (2 ) ,146-149 More Information

Luggen M.;Belhorn L.;Evans T.;Fitzgerald O.;Spencer-Green G. (01-01-1995. ) The evolution of Raynaud's phenomenon: A longterm prospective study .Journal of Rheumatology, , 22 (12 ) ,2226-2232

Tugwell P.;Bombardier C.;Buchanan W.W.;Goldsmith C.;Grace E.;Bennett K.J.;Williams H.J.;Egger M.;Alarcon G.S.;Guttadauria M.;Yarboro C.;Polisson R.P.;Szydlo L.;Luggen M.E.;Billingsley L.M.;Ward J.R.;Marks C. (03-20-1990. ) Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-ite.Archives of Internal Medicine, , 150 (1 ) ,59-62 More Information

Luggen M.;Hess E.;Gartside P. (01-01-1990. ) Measure of relative value of drugs in RA (I: Reply) .Journal of Rheumatology, , 17 (7 ) ,979

Williams H.J.;Furst D.E.;Dahl S.L.;Steen V.D.;Marks C.;Alpert E.J.;Henderson A.M.;Samuelson C.O.;Dreyfus J.N.;Weinstein A.;Maclaughlin E.J.;Alarcón G.S.;Kaplan S.B.;Guttadauria M.;Luggen M.E.;Reading J.C.;Egger M.J.;Ward J.R. (01-01-1985. ) Double?blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline fo.Arthritis & Rheumatism, , 28 (3 ) ,308-314 More Information

1986 Fellow - American College of Rheumatology

1992 Fellow - American College of Physicians

2002 -2007 Top Rheumatologist by Castle-Connolly

Member of US News & World Report's 50 Best Rheumatology Patient Care Programs Christ Hospital

Immunology, Rheumatology, Arthritis, Autoimmune Diseases

Academic - Health Professions Building
3255 Eden Avenue
Cincinnati  Ohio, 45267-0563
Phone: 513-558-5535
Fax: 513-558-3799
michael.luggen@uc.edu